➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Express Scripts
Moodys
Medtronic
Johnson and Johnson

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,067,431

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,067,431 protect, and when does it expire?

Patent 8,067,431 protects MOVANTIK and is included in one NDA.

This patent has forty-two patent family members in twenty-four countries.

Summary for Patent: 8,067,431
Title:Chemically modified small molecules
Abstract: Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.
Inventor(s): Fishburn; C. Simone (Redwood City, CA), Lechuga-Ballesteros; David (San Jose, CA), Viegas; Tacey (Madison, AL), Kuo; Mei-Chang (Palo Alto, CA), Song; Yuan (Belmont, CA), Gursahani; Hema (Foster City, CA), Leach; Chester (Tijeras, NM)
Assignee: Nektar Therapeutics (San Francisco, CA)
Application Number:12/710,167
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 8,067,431

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Redhill MOVANTIK naloxegol oxalate TABLET;ORAL 204760-001 Sep 16, 2014 RX Yes No   Start Trial   Start Trial TREATMENT OF OPIOID-INDUCED CONSTIPATION   Start Trial
Redhill MOVANTIK naloxegol oxalate TABLET;ORAL 204760-002 Sep 16, 2014 RX Yes Yes   Start Trial   Start Trial TREATMENT OF OPIOID-INDUCED CONSTIPATION   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Colorcon
Dow
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.